ESPE Abstracts

Introduction: GLP-1 analogues are promising agents for the pharmacotherapy of obesity due to their combined effect on metabolic signalization and eating behavior. The GLP-1 analog liraglutide is registered in Europe for therapy of obese adolescents aged 12-17 years since 2021. According to clinical studies, liraglutide administration leads to a mean weight loss 4.6%. We summarize early real-life experience with this novel therapy.<strong...

Background: Neonatal hyperinsulinaemic hypoglycaemia (HH) has recently been recognized as a consequence of mutations in HNF1A, which also cause maturity-onset diabetes of the young (MODY) later in life.Aims: To report phenotypic and genetic investigations of two patients with functional characterisation of identified mutations in HNF1A.Case reports: Two unrelated patients presented with HH requiring i.v. glucose a...

Introduction: The genetic investigation of tall stature (TS) is routinely indicated only in children with clinical suspicion of a specific syndrome associated with TS. After ruling out an endocrine disorder, the remaining tall children mostly receive a clinical diagnosis of “idiopathic” (ITS) or “familial” tall stature (FTS). The aetiology of their TS remains unknown.Aims: To elucidate genetic cau...